表紙
市場調査レポート

Cyclokat(ドライアイ治療薬)の市場分析と将来予測

Cyclokat (Dry Eye Syndrome) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 249481
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
Cyclokat(ドライアイ治療薬)の市場分析と将来予測 Cyclokat (Dry Eye Syndrome) - Forecast and Market Analysis to 2022
出版日: 2013年07月31日 ページ情報: 英文 56 Pages
概要

当レポートでは、ドライアイの治療薬の一つ、Cyclokat(シクロカット)の世界市場について分析し、ドライアイの概要や治療法、競合する企業・薬品の概要、アンメットニーズと市場機会、CF101の商品情報(特色・効能・安全性など)、世界の主要国における市場販売額の見通し(今後10年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 分析背景
  • 関連調査

第3章 疾患の概要

  • 病因・病態
    • 病因
    • 病態
    • 分類
    • 予後
    • 生活の質(QOL)
  • 兆候

第4章 疾患の管理

  • 概要
    • 診断の概要
    • 治療のガイドライン
    • 治療の概要

第5章 競争環境

  • 概要
  • 競合企業の戦略的評価

第6章 市場機会とアンメットニーズ

  • 概要
  • 診断検査は患者をサブグループ・レベルまで判別できるほど明快ではない
  • 頻繁な投与と副作用が、服薬制限の制約となる
  • 医師・患者の認知度の不足
  • 治験のデザインが、ほとんどの薬剤が認証されないという現状の要因となり得る
  • アンメットニーズのギャップの分析
  • ドライアイの兆候・深刻度を計測する包括的な手法
  • 軽症患者の治療率の向上

第7章 パイプライン評価

  • 概要
  • 治験中の有望な薬剤

第8章 Cyclokatについて

  • 概要
  • 効能
  • 安全性
  • 投薬・調合
  • 臨床面での潜在的な位置づけ
  • 商業面での潜在的な位置づけ
  • 価格設定と医療費償還
  • SWOT分析
  • 予測

第9章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC191DFR

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

Cyclokat is under investigation for the treatment of moderate to severe dry eye. It is a preservative-free cationic emulsion of CsA that uses Novagali's patented Novasorb technology. The cationic formulation of CsA has been demonstrated to be more effective in penetrating the ocular surface than the anionic Restasis formulation in head-to-head pharmacokinetic studies. Novasorb is based on the electrostatic attraction that occurs between the droplets of a positively-charged emulsion and the eye mucus and epithelia, including the epithelium of the cornea and conjunctiva, which are all negatively charged. Cyclokat employs this attraction to optimize the absorption of CsA onto the ocular surface, making once-a-day dosing possible.

Scope

  • Overview of DES, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cyclokat including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cyclokat for the top two countries from 2012 to 2022.
  • Sales information covered for Japan and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for DES
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Cyclokat performance
  • Obtain sales forecast for Cyclokat from 2012-2022 in top two countries (Japan and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Classification
    • 3.1.4. Prognosis
    • 3.1.5. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis Overview
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Diagnostic tests are not specific enough to identify subgroups of patients
  • 6.3. Frequent dosing and side effects limit compliance
  • 6.4. Lack of physician and patient awareness
  • 6.5. Trial design may be a factor in so few drugs being approved
  • 6.6. Unmet Needs Gap Analysis
  • 6.7. Comprehensive method for measuring dry eye signs and severity levels
  • 6.8. Increase treatment rates among milder forms of the disease

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising drugs in clinical development

8. Cyclokat

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement

8.8. SWOT Analysis

  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed DES patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Individual Drug Assumptions
    • 9.4.5. Generic Erosion
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Contact Us
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Dry Eye Syndrome
  • Table 2: Treatment Guidelines for Dry Eye Syndrome
  • Table 3: Commonly Prescribed Drugs for Dry Eye Syndrome by Class in the Global Markets, 2012
  • Table 4: Leading Treatments for Dry Eye Syndrome, 2012
  • Table 5: Overall Unmet Needs - Current Level of Attainment
  • Table 6: Clinical Unmet Needs - Gap Analysis, 2012
  • Table 7: Dry Eye Syndrome - Phase Pipeline, 2012
  • Table 8: Comparison of Therapeutic Classes in Development for Dry Eye Syndrome, 2012
  • Table 9: Product Profile - Cyclokat
  • Table 10: Cyclokat SWOT Analysis, 2012
  • Table 11: Global Sales Forecasts ($m) for Cyclokat, 2012-2022

List of Figures

  • Figure 1: Dry Eye Syndrome - Disease Etiology
  • Figure 2: Tear Film in Normal Eye and Dry Eye
  • Figure 3: Sequence of Diagnostic Tests Used to Diagnose Dry Eye Syndrome
  • Figure 4: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome Without Lid Margin Disease, 2006
  • Figure 5: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome With Lid Margin Disease and Abnormal Tear Distribution, 2006
  • Figure 6: Treatment Recommendations for Dry Eye Syndrome from the Management and Therapy Subcommittee, Dry Eye Workshop, 2007
  • Figure 7: American Academy of Ophthalmology Preferred Practice Pattern for Dry Eye, 2011
  • Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in Dry Eye Syndrome, 2012-2022
Back to Top